Rapamycin analog with reduced immunosuppressive profile
Tornado Therapeutics · published 2025-05-18 · filed 2023-12-04
▸ inventors
K. Tanaka, Y. Mori
▸ abstract
An mTORC1-selective rapalog reducing FKBP12-FRB binding affinity to mTORC2, preserving lifespan-extension benefits while minimizing T-cell suppression.
▸ topics
▸ source links
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation
